Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Nat Cancer. 2020 Mar 23;1(4):382–393. doi: 10.1038/s43018-020-0047-1

Extended Data Fig. 5. Mutational signatures in two hypermutated cases with acquired PTEN mutations.

Extended Data Fig. 5

96 base substitution profiles of pre-treatment ctDNA samples from the two hypermutated cases that eventually developed PTEN mutations under therapy showing dominant APOBEC signatures (Signatures 2 and 13).